Jagsonpal Pharma
Jagsonpal Pharma is a pharmaceutical company selling a drug portfolio focused on gynaecology and orthopaedic segments in India's pharmaceutical market.
- Public company
- Gurugram, HR, INIndia
Jagsonpal Pharma is a pharmaceutical company selling a drug portfolio focused on gynaecology and orthopaedic segments in India's pharmaceutical market.
jagsonpal.comCrawled Nov 6, 2026
Doxypal DR-LLorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.View More
Jagsonpal Pharmaceuticals monitors pharmaceutical safety, including drug interactions and effects on vulnerable groups like children, the elderly, and pregnant women.
The company supports community development in its operational regions, focusing on economically marginalized groups through long-term projects.
Sl.No. Description Download 1 CSR Projects approved by the Board of Directors
Jagsonpal builds partnerships based on safety, responsibility, trust, and integrity to develop affordable and quality healthcare solutions.
Jagsonpal Pharmaceuticals Limited, founded in 1978, acquired a controlling stake in AEQUITAS HEALTHCARE and specializes in gynaecology and infertility treatments.
Jagsonpal Pharmaceuticals Limited’s board approves a share buyback plan. The company, which operates in the pharmaceutical sector, has authorized the initiative to potentially return value to shareholders. The buyback plan was announced on March 12, 2026.
Mar 2026MarketScreenerNews article
Jagsonpal Pharmaceuticals Limited releases its financial performance for the third quarter and nine months ending December 31, 2025. The report covers key metrics and operational updates for investors and stakeholders. Details include revenue trends, profitability, and segment-wise growth for the period.
Jan 2026MarketScreenerNews article
Jagsonpal Pharmaceuticals reports a **29.12% sequential revenue increase** in Q2 FY26, reaching ₹58.56 crores, driven by seasonal demand and a stronger product mix. Operating profit (excluding other income) rises to **₹14.21 crores**, up from ₹10.24 crores in the same quarter last year, showcasing improved operational efficiency. The company’s profitability metrics mark its strongest performance in recent quarters despite broader market valuation concerns.
Nov 2025Markets MojoNews article
Jagsonpal Pharmaceuticals Limited acquires Resilient Cosmeceuticals Private Limited’s India business for **INR 240 million**, covering assets and operations. The deal, finalized in **February 2025**, is funded entirely through equity. The target’s reported turnover was **INR 165.8 million** prior to the transaction.
Feb 2025MarketScreener IndiaNews article